GleamWall
中文EN

TMCI TREACE MEDICAL CONCEPTS, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1630627 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-7.1%
TTM net income YoY-11.3%
TTM EPS YoY-6.2%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—

Margins

Gross margin79.6%
Operating margin-24.4%
Net margin-27.4%
FCF margin-9.1%
EBITDA margin-21.1%

Returns

ROE-74.0%
ROA-29.7%
ROIC (approx.)-31.2%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets65.6%
Debt / equity0.97x
Current ratio2.58x
Interest coverage-8.17x

Cash quality & payout

Operating cash flow / net income0.16x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue4.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$48.25M$45.38M$47.20M$62.52M$50.21M$47.39M$52.57M$68.71M
Cost of revenue$9.90M$9.77M$9.79M$12.12M$10.51M$9.63M$10.68M$13.23M
Gross profit$38.35M$35.61M$37.41M$50.40M$39.71M$37.75M$41.89M$55.48M
R&D expense$4.49M$4.38M$4.62M$4.54M$4.68M$5.50M$5.56M$5.21M
SG&A expense$15.68M$15.25M$16.18M$14.53M$16.28M$16.14M$15.79M$13.61M
Operating income-$11.53M-$14.96M-$17.17M-$5.92M-$15.68M-$16.97M-$15.58M-$204,000
Interest expense$1.58M$1.56M$1.57M$1.35M$1.34M$1.32M$1.31M$1.31M
Net income-$12.57M-$15.87M-$17.96M-$9.39M-$16.29M-$17.40M-$15.92M-$501,000
EBITDA-$10.03M-$13.46M-$16.27M-$3.11M-$13.18M-$14.67M-$13.12M$2.03M
EPS (basic)-0.19-0.24-0.28—-0.26-0.28-0.25—
EPS (diluted)-0.19-0.24-0.28—-0.26-0.28-0.25—
Weighted avg. shares (diluted)65.46M65.05M64.59M—63.52M63.01M62.66M—
Balance sheet
Cash & equivalents$7.76M$12.61M$9.54M$10.71M$7.69M$8.05M$13.37M$11.35M
Short-term investments$32.04M$33.01M$42.31M$37.66M$49.73M$61.24M$62.72M$64.33M
Receivables$30.22M$28.73M$30.36M$42.16M$32.96M$30.33M$31.11M$40.80M
Inventory$42.30M$39.54M$36.37M$36.03M$41.42M$42.40M$37.94M$39.26M
Current assets$118.69M$120.45M$123.47M$132.05M$138.00M$147.60M$149.44M$161.40M
PP&E, net$33.04M$32.50M$32.06M$29.75M$29.97M$29.71M$27.13M$25.95M
Goodwill$12.81M$12.81M$12.81M$12.81M$12.81M$12.81M$12.81M$12.81M
Intangibles$6.41M$6.65M$6.89M$7.12M$7.36M$7.60M$7.84M$8.07M
Total assets$179.30M$181.06M$184.10M$190.58M$196.59M$206.44M$205.85M$217.09M
Current liabilities$46.08M$41.50M$34.49M$30.64M$40.91M$41.90M$33.18M$34.92M
Short-term debt$3.78M$3.17M$1.78M$1.75M$1.80M$1.11M$45,000$0
Long-term debt$56.26M$56.04M$55.82M$55.58M$53.53M$53.45M$53.38M$53.31M
Total debt$60.05M$59.21M$57.60M$57.33M$55.33M$54.57M$53.42M$53.31M
Total liabilities$117.65M$113.32M$106.91M$103.25M$107.40M$108.83M$100.50M$104.20M
Shareholders' equity$61.65M$67.74M$77.19M$87.33M$89.19M$97.61M$105.34M$112.89M
Net debt$52.28M$46.60M$48.05M$46.62M$47.64M$46.52M$40.05M$41.96M
Cash flow statement
Operating cash flow-$3.25M-$4.70M$7.24M-$8.03M-$9.09M-$3.05M$4.20M-$4.21M
Capital expenditure$2.17M$2.20M$3.06M$2.40M$2.81M$4.77M$3.54M$3.07M
Free cash flow-$5.43M-$6.90M$4.18M-$10.42M-$11.90M-$7.82M$655,000-$7.28M
Investing cash flow-$1.26M$7.07M-$7.82M$9.67M$8.74M-$3.26M-$1.89M$3.42M
Financing cash flow-$335,000$696,000-$588,000$1.38M-$10,000$987,000-$282,000$26,000
Depreciation & amortization$1.50M$1.50M$899,000$2.81M$2.50M$2.30M$2.46M$2.24M
Stock-based compensation$6.93M$6.46M$8.03M$7.55M$8.00M$9.58M$8.69M$8.55M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.